Search

Your search keyword '"Thorburn, Christine"' showing total 27 results
Start Over Author "Thorburn, Christine"
27 results on '"Thorburn, Christine"'

1. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

Author

Peffault de Latour, Régis, primary, Röth, Alexander, additional, Kulasekararaj, Austin G., additional, Han, Bing, additional, Scheinberg, Phillip, additional, Maciejewski, Jaroslaw P., additional, Ueda, Yasutaka, additional, de Castro, Carlos M., additional, Di Bona, Eros, additional, Fu, Rong, additional, Zhang, Li, additional, Griffin, Morag, additional, Langemeijer, Saskia M.C., additional, Panse, Jens, additional, Schrezenmeier, Hubert, additional, Barcellini, Wilma, additional, Mauad, Vitor A.Q., additional, Schafhausen, Philippe, additional, Tavitian, Suzanne, additional, Beggiato, Eloise, additional, Chew, Lee Ping, additional, Gaya, Anna, additional, Huang, Wei-Han, additional, Jang, Jun Ho, additional, Kitawaki, Toshio, additional, Kutlar, Abdullah, additional, Notaro, Rosario, additional, Pullarkat, Vinod, additional, Schubert, Jörg, additional, Terriou, Louis, additional, Uchiyama, Michihiro, additional, Wong Lee Lee, Lily, additional, Yap, Eng-Soo, additional, Sicre de Fontbrune, Flore, additional, Marano, Luana, additional, Alashkar, Ferras, additional, Gandhi, Shreyans, additional, Trikha, Roochi, additional, Yang, Chen, additional, Liu, Hui, additional, Kelly, Richard J., additional, Höchsmann, Britta, additional, Kerloeguen, Cécile, additional, Banerjee, Partha, additional, Levitch, Rafael, additional, Kumar, Rakesh, additional, Wang, Zhixin, additional, Thorburn, Christine, additional, Maitra, Samopriyo, additional, Li, Shujie, additional, Verles, Aurelie, additional, Dahlke, Marion, additional, and Risitano, Antonio M., additional

Published
2024
Full Text
View/download PDF

2. MDS-278 Substantial Increases in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size With Oral Iptacopan Monotherapy Confirms Control of Hemolysis in Complement Inhibitor-Naive PNH Patients

Author

de Latour, Régis Peffault, primary, Han, Bing, additional, Maciejewski, Jaroslaw, additional, Ueda, Yasutaka, additional, Fu, Rong, additional, Zhang, Li, additional, Kulasekararaj, Austin, additional, Röth, Alexander, additional, Chew, Lee Ping, additional, Jang, Jun Ho, additional, Lee, Lily Wong Lee, additional, Panse, Jens, additional, Yap, Eng-Soo, additional, Marano, Luana, additional, de Fontbrune, Flore Sicre, additional, Yang, Chen, additional, Banerjee, Partha, additional, Wang, Zhixin, additional, Thorburn, Christine, additional, Li, Shujie, additional, Dahlke, Marion, additional, and Risitano, Antonio, additional

Published
2023
Full Text
View/download PDF

3. MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia

Author

Risitano, Antonio M., primary, Röth, Alexander, additional, Kulasekararaj, Austin, additional, Scheinberg, Phillip, additional, Ueda, Yasutaka, additional, de Castro, Carlos, additional, Di Bona, Eros, additional, Griffin, Morag, additional, Langemeijer, Saskia MC, additional, Schrezenmeier, Hubert, additional, Barcellini, Wilma, additional, Mauad, Vitor AQ, additional, Panse, Jens, additional, Schafhausen, Philippe, additional, Tavitian, Suzanne, additional, Beggiato, Eloise, additional, Gaya, Anna, additional, Huang, Wei-Han, additional, Kitawaki, Toshio, additional, Kutlar, Abdullah, additional, Maciejewski, Jaroslaw, additional, Notaro, Rosario, additional, Pullarkat, Vinod, additional, Schubert, Jörg, additional, Terriou, Louis, additional, Uchiyama, Michihiro, additional, de Fontbrune, Flore Sicre, additional, Marano, Luana, additional, Alashkar, Ferras, additional, Gandhi, Shreyans, additional, Kerloeguen, Cécile, additional, Kumar, Rakesh, additional, Thorburn, Christine, additional, Maitra, Samopriyo, additional, Dahlke, Marion, additional, and de Latour, Régis Peffault, additional

Published
2023
Full Text
View/download PDF

4. POSTER: MDS-278 Substantial Increases in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size With Oral Iptacopan Monotherapy Confirms Control of Hemolysis in Complement Inhibitor-Naive PNH Patients

Author

de Latour, Régis Peffault, primary, Han, Bing, additional, Maciejewski, Jaroslaw, additional, Ueda, Yasutaka, additional, Fu, Rong, additional, Zhang, Li, additional, Kulasekararaj, Austin, additional, Röth, Alexander, additional, Chew, Lee Ping, additional, Jang, Jun Ho, additional, Lee, Lily Wong Lee, additional, Panse, Jens, additional, Yap, Eng-Soo, additional, Marano, Luana, additional, de Fontbrune, Flore Sicre, additional, Yang, Chen, additional, Banerjee, Partha, additional, Wang, Zhixin, additional, Thorburn, Christine, additional, Li, Shujie, additional, Dahlke, Marion, additional, and Risitano, Antonio, additional

Published
2023
Full Text
View/download PDF

5. POSTER: MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia

Author

Risitano, Antonio M., primary, Röth, Alexander, additional, Kulasekararaj, Austin, additional, Scheinberg, Phillip, additional, Ueda, Yasutaka, additional, de Castro, Carlos, additional, Di Bona, Eros, additional, Griffin, Morag, additional, Langemeijer, Saskia MC, additional, Schrezenmeier, Hubert, additional, Barcellini, Wilma, additional, Mauad, Vitor AQ, additional, Panse, Jens, additional, Schafhausen, Philippe, additional, Tavitian, Suzanne, additional, Beggiato, Eloise, additional, Gaya, Anna, additional, Huang, Wei-Han, additional, Kitawaki, Toshio, additional, Kutlar, Abdullah, additional, Maciejewski, Jaroslaw, additional, Notaro, Rosario, additional, Pullarkat, Vinod, additional, Schubert, Jörg, additional, Terriou, Louis, additional, Uchiyama, Michihiro, additional, de Fontbrune, Flore Sicre, additional, Marano, Luana, additional, Alashkar, Ferras, additional, Gandhi, Shreyans, additional, Kerloeguen, Cécile, additional, Kumar, Rakesh, additional, Thorburn, Christine, additional, Maitra, Samopriyo, additional, Dahlke, Marion, additional, and de Latour, Régis Peffault, additional

Published
2023
Full Text
View/download PDF

6. P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS

Author

Peffault de Latour, Régis, primary, Han, Bing, additional, Maciejewski, Jaroslaw P, additional, Ueda, Yasutaka, additional, Fu, Rong, additional, Zhang, LI, additional, Kulasekararaj, Austin, additional, Röth, Alexander, additional, Ping Chew, Lee, additional, Ho Jang, Jun, additional, Wong, Lily L L, additional, Panse, Jens, additional, Yap, Eng-Soo, additional, Marano, Luana, additional, Sicre de Fontbrune, Flore, additional, Yang, Chen, additional, Banerjee, Partha, additional, Wang, Zhixin, additional, Thorburn, Christine, additional, LI, Shujie, additional, Dahlke, Marion, additional, and Maria Risitano, Antonio, additional

Published
2023
Full Text
View/download PDF

7. S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA

Author

Risitano, Antonio Maria, primary, Röth, Alexander, additional, Kulasekararaj, Austin, additional, Scheinberg, Phillip, additional, Ueda, Yasutaka, additional, de Castro, Carlos, additional, Bona, Eros DI, additional, Griffin, Morag, additional, Langemeijer, Saskia, additional, Schrezenmeier, Hubert, additional, Barcellini, Wilma, additional, Mauad, Vitor Aq, additional, Panse, Jens, additional, Schafhausen, Philippe, additional, Tavitian, Suzanne, additional, Beggiato, Eloise, additional, Gaya, Anna, additional, Huang, Wei-Han, additional, Kitawaki, Toshio, additional, Kutlar, Abdullah, additional, Maciejewski, Jaroslaw P, additional, Notaro, Rosario, additional, Pullarkat, Vinod, additional, Schubert, Jörg, additional, Terriou, Louis, additional, Uchiyama, Michihiro, additional, de Fontbrune, Flore Sicre, additional, Marano, Luana, additional, Alashkar, Ferras, additional, Gandhi, Shreyans, additional, Kerloëguen, Cécile, additional, Kumar, Rakesh, additional, Thorburn, Christine, additional, Maitra, Samopriyo, additional, Dahlke, Marion, additional, and de Latour, Régis Peffault, additional

Published
2023
Full Text
View/download PDF

11. Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Author

Peffault de Latour, Regis, primary, Roeth, Alexander, additional, Kulasekararaj, Austin, additional, Scheinberg, Phillip, additional, Ueda, Yasutaka, additional, de Castro, Carlos M, additional, Di Bona, Eros, additional, Schrezenmeier, Hubert, additional, Langemeijer, Saskia MC, additional, Barcellini, Wilma, additional, Tavitian, Suzanne, additional, Panse, Jens, additional, Schafhausen, Philippe, additional, Mauad, Vitor AQ, additional, Kerloeguen, Cecile, additional, Levitch, Rafael, additional, Kumar, Rakesh, additional, Thorburn, Christine, additional, Maitra, Samopriyo, additional, Dahlke, Marion, additional, and Risitano, Antonio M, additional

Published
2022
Full Text
View/download PDF

15. Clinical Breakthrough Hemolysis (BTH) during Monotherapy with the Oral Factor B Inhibitor Iptacopan Is Generally Not Severe and Managed without Treatment Discontinuation: 48-Week Data from the Phase III Apply-PNH and Appoint-PNH Trials in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Author

Peffault De Latour, Regis, Kulasekararaj, Austin, Scheinberg, Phillip, Ferber, Philippe, Lawniczek, Tomasz, Thorburn, Christine, Dahlke, Marion, and Risitano, Antonio M

Published
2023
Full Text
View/download PDF

16. Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Author

Risitano, Antonio M, Kulasekararaj, Austin, Roeth, Alexander, Scheinberg, Phillip, Ueda, Yasutaka, de Castro, Carlos, Di Bona, Eros, Griffin, Morag, Langemeijer, Saskia MC, Schrezenmeier, Hubert, Barcellini, Wilma, Mauad, Vitor AQ, Panse, Jens, Schafhausen, Philippe, Tavitian, Suzanne, Beggiato, Eloise, Gaya, Anna, Huang, Wei-Han, Kitawaki, Toshio, Kutlar, Abdullah, Maciejewski, Jaroslaw P., Notaro, Rosario, Pullarkat, Vinod, Schubert, Jörg, Terriou, Louis, Uchiyama, Michihiro, Sicre De Fontbrune, Flore, Frieri, Camilla, Alashkar, Ferras, Gandhi, Shreyans, Kumar, Rakesh, Thorburn, Christine, Maitra, Samopriyo, Solar-Yohay, Susan, Lawniczek, Tomasz, Dahlke, Marion, and Peffault De Latour, Régis

Published
2023
Full Text
View/download PDF

26. A Randomized, Blinded, Parallel Group, Placebo Controlled Pilot Study Evaluating the Effect of PVAC Treatment in Patients with Diffuse Systemic Sclerosis

Author

Genovese, Mark, Chakravarty, Eliza, Boyle, David, Tutuncu, Zuhre, Thorburn, Christine, Halilhodzic, Merita, Kroll, Stewart, Baughman, Jan, Stewart, Stanford, and Kavanaugh, Arthur

Abstract

OBJECTIVE: Systemic sclerosis (SSc) is a disorder characterized by progressive thickening of the skin; there is no effective therapy. PVAC, a potential therapeutic agent derived from delipidated, deglycolipidated Mycobacterium vaccae, has shown effects on cutaneous disease in animal models of SSc. We evaluated the safety and possible biologic effect of intradermal injections of PVAC in patients with diffuse SSc. METHODS: Eighteen patients enrolled in this double blind, placebo controlled, randomized, 24 week pilot study. All patients met criteria for diffuse SSc without evidence of significant renal dysfunction, pulmonary fibrosis, pulmonary hypertension, or congestive heart failure. Patients received 8 intradermal injections of 15 µg PVAC, 50 µg PVAC, or placebo at 3 week intervals. The primary efficacy endpoint was the change in Modified Rodnan Skin Score (MRSS) at Week 24. Each of the active drug arms was compared to placebo. RESULTS: Baseline demographic and disease characteristics were similar across the 3 treatment groups. The median age was 48 years and 14 of 18 (78%) patients were female. The regimens were well tolerated with no reported serious adverse events; however, grade 1 or 2 injection site reactions occurred in the majority of patients receiving PVAC. The MRSS improved by 20.6% in the 15 µg PVAC arm, while it worsened by 29.8% in the placebo arm and by 16.7% in the 50 µg arm. Change in physician and patient global assessments followed similar trends. CONCLUSION: In this pilot study, use of PVAC in patients with SSc appeared safe and was associated with a trend toward improved skin scores in the 15 µg treatment group. Additional evaluation of this therapeutic approach is warranted.

Published
2005

27. Bacteriological Efficacies of Three Macrolides Compared with Those of Amoxicillin-Clavulanate againstStreptococcus pneumoniaeand Haemophilus influenzae

Author

Berry, Valerie, Thorburn, Christine E., Knott, Sarah J., and Woodnutt, Gary

Abstract

ABSTRACTComparative antibacterial efficacies of erythromycin, clarithromycin, and azithromycin were examined againstStreptococcus pneumoniaeand Haemophilus influenzae, with amoxicillin-clavulanate used as the active control. In vitro, the macrolides at twice their MICs and at concentrations achieved in humans were bacteriostatic or reduced the numbers of viable S. pneumoniaeslowly, whereas amoxicillin-clavulanate showed a rapid antibacterial effect. AgainstH. influenzae, erythromycin, clarithromycin, and clarithromycin plus 14-hydroxy clarithromycin at twice their MICs produced a slow reduction in bacterial numbers, whereas azithromycin was bactericidal. Azithromycin at the concentrations achieved in the serum of humans was bacteriostatic, whereas erythromycin and clarithromycin were ineffective. In experimental respiratory tract infections in rats, clarithromycin (equivalent to 250 mg twice daily [b.i.d.]) and amoxicillin-clavulanate (equivalent to 500 plus 125 mg b.i.d., respectively) were highly effective against S. pneumoniae, but azithromycin (equivalent to 500 and 250 mg once daily) was significantly less effective (P< 0.01). Against H. influenzae, clarithromycin treatment (equivalent to 250 or 500 mg b.i.d.) was similar to no treatment and was significantly less effective than amoxicillin-clavulanate treatment (P< 0.01). Azithromycin demonstrated significant in vivo activity (P< 0.05) but was significantly less effective than amoxicillin-clavulanate (P< 0.05). Overall, amoxicillin-clavulanate was effective in vitro and in vivo. Clarithromycin and erythromycin were ineffective in vitro and in vivo against H. influenzae, and azithromycin (at concentrations achieved in humans) showed unreliable activity against both pathogens. These results may have clinical implications for the utility of macrolides in the empiric therapy of respiratory tract infections.

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results